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Abstract
Background: The World Health Organization (WHO), like many other organisations around the world, has recognised the need to use more
rigorous processes to ensure that health care recommendations are informed by the best available research evidence. This is the third of a series of
16 reviews that have been prepared as background for advice from the WHO Advisory Committee on Health Research to WHO on how to achieve
this.
Objective: In this review we address the composition of guideline development groups and consultation processes during guideline development.
Methods: We searched PubMed and three databases of methodological studies for existing systematic reviews and relevant methodological
research. We did not conduct systematic reviews ourselves. Our conclusions are based on the available evidence, consideration of what WHO and
other organisations are doing and logical arguments.
Key questions and answers: What should be the composition of a WHO-panel that is set up to develop recommendations?
The existing empirical evidence suggests that panel composition has an impact on the content of the recommendations that are made. There is limited
research evidence to guide the exact composition of a panel. Based on logical arguments and the experience of other organisations we recommend
the following:
• Groups that develop guidelines or recommendations should be broadly composed and include important stakeholders such as consumers, health
professionals that work within the relevant area, and managers or policy makers.
• Groups should include or have access to individuals with the necessary technical skills, including information retrieval, systematic reviewing, health
economics, group facilitation, project management, writing and editing.
• Groups should include or have access to content experts.
• To work well a group needs an effective leader, capable of guiding the group in terms of the task and process, and capable of facilitating collaboration
and balanced contribution from all of the group members.
• Because many group members will not be familiar with the methods and processes that are used in developing recommendations, groups should
be offered training and support to help ensure understanding and facilitate active participation.
What groups should be consulted when a panel is being set up?
We did not identify methodological research that addressed this question, but based on logical arguments and the experience of other organisations
we recommend that as many relevant stakeholder groups as practical should be consulted to identify suitable candidates with an appropriate mix of
perspectives, technical skills and expertise, as well as to obtain a balanced representation with respect to regions and gender.
What methods should WHO use to ensure appropriate consultations?
We did not find any references that addressed issues related to this question. Based on logical arguments and the experience of other organisations
we believe that consultations may be desirable at several stages in the process of developing guidelines or recommendations, including:
• Identifying and setting priorities for guidelines and recommendations
• Commenting on the scope of the guidelines or recommendations
• Commenting on the evidence that is used to inform guidelines or recommendations
• Commenting on drafts of the guidelines or recommendations
• Commenting on plans for disseminating and supporting the adaptation and implementation of the guidelines or recommendations.
• Key stakeholder organisations should be contacted directly whenever possible.
• Consultation processes should be transparent and should encourage feedback from interested parties.
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Background
The World Health Organization (WHO), like many other
organisations around the world, has recognised the need
to use more rigorous processes to ensure that health care
recommendations are informed by the best available
research evidence. This is the third of a series of 16 reviews
that have been prepared as background for advice from
the WHO Advisory Committee on Health Research to
WHO on how to achieve this.
Health care recommendations that are systematically and
transparently developed and well informed by the best
available evidence require several types of evidence and
judgements. Judgements must be made about:
• The expected effects of the options that are being consid-
ered,
• Factors that might modify the expected effects in specific
settings,
• Needs, risks and resources in specific settings,
• Ethical, legal and political constraints, and
• The balance between the expected benefits harms and
costs if a recommendation is implemented.
A group developing recommendations must be capable of
assessing the evidence that is available to inform these
judgements and to make all of these different types of
judgements. In this paper we address the following ques-
tions:
• What should be the composition of a WHO-panel that
is set up to develop recommendations?
• What groups should be consulted when a panel is being
set up?
• What methods should WHO use to ensure appropriate
consultations?
Questions related to group processes or integrating values
and consumer involvement are addressed in two other
papers in this series [1,2].
What WHO is doing now
Expert committees are sometimes used by WHO to pro-
vide guidance. The Director General selects committee
members from WHO's expert advisory panels. The mem-
bers of these panels are primarily included based on "their
technical ability and experience". When an expert com-
mittee is assembled it should have: "equitable geographi-
cal representation, gender balance, a balance of experts
from developed and developing countries, representation
of different trends of thought, approached and practical
experience in various parts of the world, and an appropri-
ate interdisciplinary balance" [3].
Establishing an expert committee is a formal process with
regulations established by the World Health Assembly.
Many WHO recommendations are not developed by
expert committees. Less formal procedures that are not
subject to the Regulations for Expert Advisory Panels and
Committees are frequently used to convene groups that
develop guidelines or recommendations. "Consultations"
or "proceedings" also frequently provide the basis for rec-
ommendations. Consumers or representatives of the gen-
eral public are rarely included in groups that develop
recommendations.
The Guidelines for WHO Guidelines state that the "Tech-
nical Guidelines Development group" should be multi-
disciplinary with around 8–12 individuals representing
stakeholders (professionals, disease experts, primary care/
public health, end users, and patients) as well as method-
ologists [4]. However, up to now WHO has published few
recommendations that have adhered to these guidelines.
Broad consultations do not appear to be commonly used
to identify potential members of expert committees or
other groups that develop guidelines or recommenda-
tions. Consultations at other stages during the process of
developing recommendations are also uncommon, apart
from peer review of draft reports. Occasionally, draft rec-
ommendations may be circulated more widely.
What other organisations are doing
In a recent international survey of 152 units that support
the use of research in developing guidelines and health
policy, most respondents reported that their guidelines
development panels consisted of several stakeholders or
expert groups – often including end-users and consumers
[5]. Another review of guidelines on hypertension and
hyperlipidaemia, found that stakeholder involvement was
much lower in guidelines sponsored by specialty societies
than in guidelines sponsored by other groups [6]. A third
review of 18 prominent guideline organisations in Aus-
tralia, Canada, Europe, New Zealand and the U.S. found
that guideline development groups typically consist of 10
to 20 members and the number of disciplines per group is
often three to five [7]. Most of these programs invite meth-
odological experts (epidemiologists, library scientists and
others) and patient representatives. Most have permanent
staff providing editorial support.
Many agencies have issued guidelines for developing
guidelines [8-11] (see also our review of Guidelines for
Guidelines [12]), and all such documents that we areHealth Research Policy and Systems 2006, 4:15 http://www.health-policy-systems.com/content/4/1/15
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aware of recommend convening multi-disciplinary
groups. This includes consumers, professionals working
in the field, and individuals with the necessary methodo-
logical skills (e.g. epidemiologists, economists). Proce-
dures for recruitment of panel members are usually
prescribed or suggested, with emphasis on extensive con-
sultation with relevant stakeholder-groups.
In contrast to approaches that rely heavily on clinical
experts or research experts, as exemplified by many spe-
cialty societies [6] and the WHO, the National Institute for
Health and Clinical Excellence (NICE) in the UK does not
necessarily include experts in their guideline development
groups (GDGs): "Experts attending a GDG are present
because of their knowledge in a particular area. Therefore,
it is important that they sit within the group and enter
fully into any discussion. However, they are not full mem-
bers of the group; they do not have voting rights and
should not be involved in the final wording of recommen-
dations." The role of the professional members in the
GDG is to "represent the perspective(s) of the health care
workers involved" [10]. In an external evaluation carried
out by WHO, it was concluded that NICE is "internation-
ally a leading agency", and that the organisation "has
developed a well-deserved reputation for innovation and
methodological development" [13].
Most guidelines for guidelines highlight the importance
of having an effective leader. This person has a key role in
facilitating "the interpersonal aspects of the group proc-
esses" and ensuring "that the group works in a spirit of
collaboration, with a balanced contribution from all
members" [10].
Some agencies arrange training for members of GDGs –
particularly, but not solely, aimed at facilitating the active
participation of consumer representatives [14]. Another
suggested approach to ensure consumer involvement is to
establish separate focus groups for this purpose [10].
Wide consultation in the course of developing recommen-
dations may be done in various ways, for instance by host-
ing open meetings to discuss guideline drafts [8], or by
posting guideline drafts on the web [10]. Peer-review is
also commonly used. In the survey of 152 units that sup-
port the use of research in development of guidelines and
health policy, most reported involvement of target-users
in the selection of topics, e.g. in priority-setting groups,
through surveys or by reviewing draft lists of priority top-
ics [5]. Most respondents also reported having consumers
involved at various stages of the development process,
often by review of draft guidelines or reports [5]. In its
manual for guideline developers, NICE specifies several
stages during guideline development where consultations
with stakeholders should take place:
• When the draft scope of the guideline has been prepared
• During the selection of panel members
• When the full draft version of the guidelines is com-
pleted
Methods
The methods used to prepare this review are described in
the introduction to this series [15]. Briefly, the key ques-
tions addressed in this paper were vetted amongst the
authors and the ACHR Subcommittee on the Use of
Research Evidence (SURE). We searched PubMed and
three databases of methodological literature (the
Cochrane Methodology Register [16], the US National
Guideline Clearinghouse [17], and the Guidelines Inter-
national Network [18]) for existing systematic reviews
and relevant methodological research that address these
questions. We did not conduct systematic reviews our-
selves. The answers to the questions are our conclusions
based on the available evidence, consideration of what
WHO and other organisations are doing, and logical argu-
ments.
In our literature search on panel composition we used the
terms "group composition" or "panel composition" or
"'consumer involvement' and guidelines". We also
checked the reference lists of key papers and contacted key
researchers in the field. In our search on consultation
processes, we used the term "guidelines and consultation
and process".
Findings
What should be the composition of a WHO-panel that is 
set up to develop recommendations?
We identified relatively few articles on group composi-
tion. A key paper was a comprehensive report by Murphy
and colleagues from 1998, who reviewed the research lit-
erature on group composition and clinical guideline
development [19]. This systematic review identified sev-
eral studies that compared recommendations by groups
with different compositions, and several comparisons of
judgements made by homogenous subgroups of mixed
groups [19]. The authors found that "these studies,
although few in number, show that differences in group
composition may lead to different judgements. More spe-
cifically, members of a specialty are more likely to advo-
cate techniques that involve their specialty." Their
conclusion was that "these studies confirm that the com-
position of groups is important in determining the deci-
sion reached."
Knowing that groups with different compositions pro-
duce different recommendations does not necessarily tell
us what group composition will provide the most appro-Health Research Policy and Systems 2006, 4:15 http://www.health-policy-systems.com/content/4/1/15
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priate recommendations. Arguments for using multidisci-
plinary groups are largely based on logic. For example,
"Individuals' biases may be better balanced in multidisci-
plinary groups, and such balance may produce more valid
guidelines" [20]. A report from the U.S. Institute of Medi-
cine (IOM) put forward three arguments for multidiscipli-
nary groups: 1) Multidisciplinary participation increases
the probability that all relevant scientific evidence will be
located and critically evaluated; 2) Such participation
increases the likelihood that practical problems with
using guidelines will be identified and addressed; 3) Par-
ticipation helps build a sense of involvement or "owner-
ship" among different audiences for the guidelines [21].
Arguments against having narrowly focused expert groups
are based in part on research that have compared expert
recommendations to systematic reviews and which have
investigated the relationship between expertise and sys-
tematic reviews. In one study comparisons were made
between recommendations of clinical experts in textbooks
and major medical journals and results of meta-analyses
of randomized controlled trials of treatments for myocar-
dial infarction [22]. The investigators found that clinical
experts often made recommendations that were not con-
sistent with available research findings. Another study
found strong correlations between the expertise of authors
of reviews and the methods that were used in the reviews
[23]. Expertise was associated with stronger opinions
prior to conducting a review, less time spent conducting a
review, and the use of less systematic and transparent
methods.
The systematic review by Murphy and colleagues included
studies of the effects that heterogeneity has on group
judgement, and concluded that "The weight of evidence
suggest that heterogeneity in a decision-making group can
lead to a better performance than homogeneity. There is,
however, also some evidence that heterogeneity may have
an adverse effect because conflict may arise between
diverse participants" [19].
In addition, the review found few studies of the extent to
which the particular individuals that participate in a
group affect the groups' decisions. The authors concluded
that "the selection of individuals has some, but not a great
deal, of influence on outcome", based on this limited
research.
Finally, the review included research related to the opti-
mal size of groups. The authors remark that "having more
group members will increase the reliability of group
judgement", while "large groups may cause coordination
problems". They base their conclusion mainly on research
within social and organisational psychology: "It is likely
that below about six participants, reliability will decline
quite rapidly, while above about 12, improvements in
reliability will be subject to diminishing returns."
We have identified one recent study not included in the
review by Murphy et al. where recommendations made by
groups of different composition were compared [24], as
well as four studies comparing judgements made by dif-
ferent subgroups in mixed groups [25-28]. The findings,
which are consistent with the conclusions of the review,
indicate that clinical experts have a lower threshold for
rating the procedures they perform as being appropriate.
Another study, in which clinicians were surveyed about
the appropriateness of coronary angiography for various
indications, found a similar relationship [29].
We did not find any studies on the impact of group com-
position on public health or health systems recommenda-
tions. However, there is some evidence that suggests that
the same relationships between expertise and recommen-
dations that have been found for clinical recommenda-
tions are also found for public health recommendations;
i.e. that expert recommendations are frequently not con-
sistent with the available research evidence [30]. Moreo-
ver, those making public health and health policy
recommendations may frequently not systematically con-
sider potential adverse effects of public health and health
policy interventions.
We found several systematic reviews of consumer involve-
ment [31-35]. There are a number of relevant arguments
for including consumers in groups that develop recom-
mendations and descriptions of practical experience.
However, a review of comparative studies of interventions
to promote consumer involvement [31], found a "lack of
evidence from comparative studies to inform decisions
about desirable and adverse effects of consumer involve-
ment in collective decisions about health care or how to
achieve effective consumer involvement". The authors of
another systematic review, which included non-compara-
tive studies of how to involve consumers in setting the
research and development agenda for health systems [32],
recommend collaborating with "well-networked consum-
ers and providing them with information, resources and
support to empower them in key roles for consulting with
their peers." They also recommended "consultations
should engage consumer groups directly and repeatedly in
facilitated debate." See also our review on how to inte-
grate values and involve consumers in guideline develop-
ment [2].
What groups should be consulted when a panel is being set 
up?
We did not identify papers addressing this question.Health Research Policy and Systems 2006, 4:15 http://www.health-policy-systems.com/content/4/1/15
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What methods should WHO use to ensure appropriate 
consultations?
We did not identify any research findings that could
inform the answer to this question
Discussion
Based on the findings from the reports we have identified,
there is sufficient evidence to conclude that how a panel is
composed can have an important impact on conclusions
drawn by a group when making recommendations for
health care. In particular, clinical experts are more likely to
recommend procedures linked to their own specialty than
others. Furthermore, experts in a field frequently do not
employ systematic methods when reviewing evidence and
developing recommendations. These findings support the
current recommendation in the Guidelines for WHO
Guidelines: Panels should be multidisciplinary, including
a broad representation of stakeholders, as well as method-
ologists [4].
The research evidence to guide panel composition and
consultation processes is limited. However logical argu-
ments and the experience of other organisations suggest
that
• Groups that develop guidelines or recommendations
should be broadly composed and include important
stakeholders such as consumers, health professionals that
work within the relevant area, and managers or policy
makers.
• Special attention should be paid to the selection of a
group leader who has a crucial role in ensuring a positive
group process and that all voices within the group can be
heard.
• Wide consultations should be done when selecting
members of a group to develop WHO recommendations,
for example by direct contact with stakeholder groups.
• Groups should include or have access to individuals
with the necessary technical skills, including information
retrieval, systematic reviewing, health economics, group
facilitation, project management, writing and editing.
• Groups should include or have access to content experts.
• Many group members will not be familiar with the
methods and processes that are used in developing recom-
mendations, and should be offered training and support
to help ensure understanding and facilitate active partici-
pation.
The process of developing recommendations, including
the selection of group members, should be transparent.
The process should also include wide consultation that
encourages feedback at subsequent steps in the process,
which may include:
• Identifying and setting priorities for guidelines and rec-
ommendations
• Commenting on the scope of the guidelines or recom-
mendations
• Commenting on the evidence that is used to inform
guidelines or recommendations
• Commenting on drafts of the guidelines or recommen-
dations
• Commenting on plans for disseminating and support-
ing the adaptation and implementation of the guidelines
or recommendations.
• Commenting on what research should be conducted
based on the guidelines
Further work
We have not conducted an exhaustive systematic review,
but have based much of this paper on a systematic review
from 1998. We have not found subsequent studies that
provide conflicting evidence. There is, however, limited
research for the questions addressed in this report. We do
not believe that a more exhaustive review would yield a
great deal of additional evidence at this time. However, it
would be valuable for WHO or others to undertake and
keep up-to-date systematic methodology reviews that
address specific issues of group composition, including
the selection of a group leader, methods for effective con-
sultations, and methods for effective consumer involve-
ment.
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